[{'Name': 'Aclaris Therapeutics Inc', 'Country': 'USA', 'Ticker': 'ACRS', 'Sector': 'Healthcare', 'Business Type': 'Biotechnology', 'Business Model': 'Biotechnology'}, {'Pre-Tax Income': [-10.632, -4.714, -13.039, -12.871, -10.694], 'Return on Assets %': [-156.61, -27.7, -57.52, -56.16, -46.96], 'Purchase Of Property, Plant, Equipment': [-0.133, -0.132, -0.04, -0.066, -0.064], 'Book Value per Share': [-5.998, 4.589, 4.128, 4.217, 3.787], 'Return on Equity %': [0.0, -72.45, -59.36, -59.36, -49.92], '  Accounts Payable': [0.958, 0.81, 2.808, 3.309, 1.774], 'Cash Flow from Financing': [39.252, 58.057, 0.0, 18.548, 0.013], 'DeferredTaxAndRevenue': [0.178, 0.0, 0.0, 0.0, 0.0], 'Total Liabilities': [80.205, 1.555, 4.059, 5.852, 4.949], 'Additional Paid-In Capital': [0.0, 135.503, 139.08, 158.982, 160.613], '  Net Income': [-10.632, -4.714, -13.039, -12.871, -10.694], 'Other Long Term Assets': [1.966, 0.022, 0.02, 0.02, 0.02], 'Research & Development': [9.407, 2.402, 9.535, 9.836, 7.162], 'Sloan Ratio (%)': [31.78, 81.59, 69.9, 54.78, 49.87], 'Earnings Yield (Joel Greenblatt)': [0.0, -4.51, -10.5, -13.79, -8.98], 'Month End Stock Price': [26.94, 18.95, 18.47, 25.61], 'Gross Property, Plant and Equipment': [0.845, 0.402, 0.48, 0.524, 0.583], 'YoY EPS Growth (%)': [0.0, 99.98, 0.0, 0.0, 16.67], 'Operating Income': [-10.64, -4.802, -13.139, -12.989, -10.812], 'EPS (Diluted)': [-0.6, -2.852, -0.65, -0.62, -0.5], 'Quick Ratio': [20.75, 55.64, 23.29, 17.37, 18.64], 'Enterprise Value': [0.0, 458.242, 296.786, 301.248, 464.524], '  Construction In Progress': [0.077, 0.0, 0.0, 0.0, 0.0], 'eps without NRI': [-0.6, -2.85, -0.65, -0.62, -0.5], 'Other Current Assets': [0.955, 1.656, 1.587, 1.628, 1.548], 'EV-to-EBITDA': [0.0, -22.27, -9.55, -7.27, -11.16], 'Net Cash (per share)': [-2.15, 4.13, 4.03, 4.12, 3.69], 'Accounts Payable & Accrued Expense': [1.719, 1.555, 3.729, 5.507, 4.591], 'Stock Based Compensation': [0.16, 0.65, 1.22, 1.35, 1.62], 'Other Income (Expense)': [0.008, 0.088, 0.1, 0.118, 0.118], 'Shares Outstanding (EOP)': [19.41, 20.16, 20.16, 21.4, 21.42], 'Other Long-Term Liabilities': [78.305, 0.0, 0.33, 0.345, 0.358], 'Return on Capital  - Joel Greenblatt %': [-6071.33, -3143.7, -11971.75, -12210.58, -9664.36], 'Property, Plant and Equipment': [0.761, 0.36, 0.417, 0.434, 0.461], 'Net Income From Continuing Operations': [-10.632, -4.714, -13.039, -12.871, -10.694], 'Capital Expenditure': [-0.133, -0.132, -0.04, -0.066, -0.064], 'Shares Outstanding (Diluted Average)': [19.408, 6.107, 20.172, 20.663, 21.416], 'EBITDA': [-10.608, -4.769, -13.118, -12.962, -10.78], 'Net Income (Continuing Operations)': [-10.632, -4.714, -13.039, -12.871, -10.694], 'Selling, General, & Admin. Expense': [1.233, 2.4, 3.604, 3.153, 3.65], 'Price to Tangible Book': [0.0, 5.87, 4.59, 4.38, 6.76], 'Free Cashflow per Share': [-0.551, -0.699, -0.344, -0.474, -0.465], 'Cash Flow from Others': [-0.002, 0.282, 2.786, 0.004, -0.002], 'YoY EBITDA Growth (%)': [0.0, -177.94, -128.87, -371.43, 8.04], 'Altman Z-Score': [-1.65, 209.29, 55.55, 39.23, 64.76], 'Preferred dividends': [1.02, 0.213, 0.0, 0.0, 0.0], 'Depreciation, Depletion and Amortization': [0.032, 0.033, 0.021, 0.027, 0.032], 'Shares Buyback Ratio (%)': [0.0, -3.86, 0.0, -6.15, -0.09], 'Market Cap': [0.0, 543.11, 382.032, 395.258, 548.566], 'Cash, Cash Equivalents, Marketable Securities': [38.405, 84.868, 85.246, 94.01, 84.042], 'Free Cash Flow': [-10.701, -4.269, -6.934, -9.798, -9.969], 'Lowest Stock Price': [0.0, 11.05, 14.77, 16.93, 18.69], '  Change In Payables And Accrued Expense': [0.251, 0.117, 2.047, 1.799, -0.941], '  Machinery, Furniture, Equipment': [0.768, 0.402, 0.48, 0.524, 0.583], 'Retained Earnings': [-38.119, -42.833, -55.872, -68.743, -79.437], 'Total Assets': [42.087, 94.076, 87.27, 96.092, 86.071], 'EV-to-EBIT': [0.0, -22.17, -9.52, -7.25, -11.13], 'Current Ratio': [20.75, 55.64, 23.29, 17.37, 18.64], '  Change In Prepaid Assets': [-0.377, -0.505, 0.071, -0.041, 0.08], 'Shares Outstanding (Basic Average)': [19.408, 6.107, 20.172, 20.663, 21.416], 'Price to Book': [0.0, 5.87, 4.59, 4.38, 6.76], 'Change In Working Capital': [-0.126, -0.388, 2.118, 1.758, -0.861], 'Cash From Other Investing Activities': [-13.002, -69.511, -0.0, -11.282, -22.465], 'Return on Invested Capital %': [0.0, 0.0, -1870.99, 0.0, 0.0], 'EBITDA per Share': [-0.547, -0.781, -0.65, -0.627, -0.503], 'Cash Flow from Operations': [-10.568, -4.137, -6.894, -9.732, -9.905], 'Total Current Liabilities': [1.897, 1.555, 3.729, 5.507, 4.591], 'EBIT per Share': [-0.548, -0.786, -0.651, -0.629, -0.505], 'Total Current Assets': [39.36, 86.524, 86.833, 95.638, 85.59], '  Other Accrued Expense': [1.719, 1.555, 3.729, 5.507, 4.591], 'Investments And Advances': [0.0, 7.17, 0.0, 0.0, 0.0], 'Scaled Net Operating Assets': [-6.261, 0.182, -0.022, -0.043, -0.03], 'Net Current Asset Value (per share)': [-6.14, 4.21, 4.11, 4.2, 3.76], 'Earnings per Share (diluted)': [-0.6, -2.852, -0.65, -0.62, -0.5], '  Marketable Securities': [12.986, 75.017, 72.115, 62.195, 66.246], 'EPS (Basic)': [-0.6, -2.852, -0.65, -0.62, -0.5], 'Sale Of Investment': [0.017, 0.155, 10.214, 21.216, 18.402], 'Fiscal Period': [201509.0, 201512.0, 201603.0, 201606.0, 201609.0], 'Preferred Stock': [78.305, 0.0, 0.0, 0.0, 0.0], 'Accumulated other comprehensive income (loss)': [0.001, -0.149, 0.003, 0.001, -0.054], 'Net-Net Working Capital (per share)': [-6.19, 4.13, 4.03, 4.12, 3.69], 'Tangible Book per Share': [-5.998, 4.589, 4.128, 4.217, 3.787], 'Net Income': [-10.632, -4.714, -13.039, -12.871, -10.694], '  Cash And Cash Equivalents': [25.419, 9.851, 13.131, 31.815, 17.796], 'Total Equity': [-38.118, 92.521, 83.211, 90.24, 81.122], '  Accumulated Depreciation': [-0.084, -0.042, -0.063, -0.09, -0.122], 'Highest Stock Price': [0.0, 29.28, 27.37, 22.07, 25.61], 'Cash Flow from Investing': [-13.118, -69.488, 10.174, 9.868, -4.127], 'Net Change in Cash': [15.566, -15.568, 3.28, 18.684, -14.019]}]